Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q4 FY262026-06-30 | Q3 FY262026-03-31 | Q2 FY262025-12-31 | Q1 FY262025-09-30 | Q4 FY252025-06-30 | Q3 FY252025-03-31 | Q2 FY252024-12-31 | Q1 FY252024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.46B | $1.43B | $1.42B | $1.34B | $1.35B | $1.29B | $1.28B | $1.22B |
| Cost of revenue | $594.13M | $532.58M | $536.28M | $506.94M | $518.56M | $517.88M | $523.18M | $499.62M |
| Gross profit | $869.52M | $898.83M | $886.53M | $828.64M | $829.44M | $773.85M | $758.91M | $724.89M |
| Gross margin | 59.4% | 62.8% | 62.3% | 62.0% | 61.5% | 59.9% | 59.2% | 59.2% |
| Research and development | $105.73M | $94.27M | $90.97M | $87.32M | $86.44M | $83.94M | $81.37M | $79.52M |
| Selling, general and administrative | $296.28M | $285.66M | $278.40M | $259.19M | $267.16M | $245.30M | $241.61M | $238.98M |
| Operating expenses | $420.81M | $399.02M | $394.87M | $382.10M | $374.90M | $347.59M | $341.67M | $337.58M |
| Operating income | $448.71M | $499.81M | $491.66M | $446.54M | $454.54M | $426.27M | $417.24M | $387.31M |
| Operating margin | 30.7% | 34.9% | 34.6% | 33.4% | 33.7% | 33.0% | 32.5% | 31.6% |
| EBITDA | $493.49M | $558.79M | $547.48M | $510.05M | $518.17M | $469.94M | $463.68M | $432.04M |
| Interest income | $0 | $0 | $7.95M | $8.79M | $0 | $0 | −$775.00K | −$1.66M |
| Interest expense | $20.89M | $12.29M | $0 | — | $5.76M | $793.00K | $0 | — |
| Income before taxes | $474.16M | $502.31M | $496.15M | $446.79M | $458.05M | $417.69M | $418.32M | $383.50M |
| Income taxes | $90.73M | $103.58M | $103.56M | $98.26M | $78.35M | $52.65M | $73.70M | $72.14M |
| Net income | $383.43M | $398.73M | $392.59M | $348.54M | $379.71M | $365.04M | $344.62M | $311.36M |
| Net margin | 26.2% | 27.9% | 27.6% | 26.1% | 28.2% | 28.3% | 26.9% | 25.4% |
| EPS, basic | $2.65 | $2.74 | $2.69 | $2.38 | $2.59 | $2.49 | $2.35 | $2.12 |
| EPS, diluted | $2.64 | $2.74 | $2.68 | $2.37 | $2.58 | $2.48 | $2.34 | $2.11 |
| Diluted shares | 145.22M | 145.72M | 146.37M | 146.90M | 147.06M | 147.22M | 147.48M | 147.60M |
Figures describe ResMed shares, not any token. As of Aug 13, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.